Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117

International Journal of Pharmaceutics

Volumn 366, Issue 1-2, 2009, Pages 218-220

  Qian, Feng ^a   Mathias, Neil ^a   Moench, Paul ^a   Chi, Cecilia ^a   Desikan, Sridhar ^a   Hussain, Munir ^a   Smith, Ronald L ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Glucagon like peptide (GLP 1); Pharmacokinetics; Pulmonary delivery; Spray drying; Type II diabetes mellitus

Indexed keywords

BMS 686117; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MANNITOL; TREHALOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FREEZE DRYING; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPRAY DRYING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL AVAILABILITY; EXCIPIENTS; FREEZE DRYING; HYPOGLYCEMIC AGENTS; LUNG; MALE; MANNITOL; OLIGOPEPTIDES; PARTICLE SIZE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; TREHALOSE;

EID: 57849112704     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.10.020     Document Type: Article

References (22)

1. Buteau J., Roduit R., Susini S., and Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42 (1999) 856-864
2. Chege J.K., el-Araud K.A., Clark B.J., and Chrystyn H. Optimal particle size for aerosols. Thorax 52 (1997) 586-587
3. Clark A.R., Newman S.P., and Dasovich N. Mouth and oropharyngeal deposition of pharmaceutical aerosols. J. Aerosol Med. 11 (1998) S116-S121
4. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7 (2005) E20-E41
5. Davies C.N., and Muir D.C. Deposition of inhaled particles in human lungs. Nature 211 (1966) 90-91
6. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
7. Drucker D.J. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr. Pharm. Des. 7 (2001) 1399-1412
8. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
9. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., and Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 138 (1993) 159-166
10. Gedulin B.R., Smith P.A., Jodka C.M., Chen K., Bhavsar S., Nielsen L.L., Parkes D.G., and Young A.A. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int. J. Pharm. 356 (2008) 231-238
11. Hollander P.A. Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes. Med. Gen. Med. 9 (2007) 45
12. Kjems L.L., Holst J.J., Volund A., and Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52 (2003) 380-386
13. Muir D.C., and Davies C.N. The deposition of 0.5 microns diameter aerosols in the lungs of man. Ann. Occup. Hyg. 10 (1967) 161-174
14. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 8 (1993) 741-744
15. Okada H., and Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 1-99
16. Patton J.S., Bukar J., and Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev. 35 (1999) 235-247
17. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6 (2007) 67-74
18. Quattrin T. Inhaled insulin: a novel and non-invasive way for insulin administration?. Curr. Drug Saf. 1 (2006) 151-158
19. Ribel U., Larsen M.O., Rolin B., Carr R.D., Wilken M., Sturis J., Westergaard L., Deacon C.F., and Knudsen L.B. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur. J. Pharmacol. 451 (2002) 217-225
20. Robinson S.N., and Talmadge J.E. Sustained release of growth factors. In Vivo 16 (2002) 535-540
21. Shi Y., and Li L. Current advances in sustained-release systems for parenteral drug delivery. Exp. Opin. Drug Deliv. 2 (2005) 1039-1058
22. Steckel H., and Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm. 270 (2004) 297-306